Norges Bank bought a new position in Grifols, S.A. (NASDAQ:GRFS – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,940,000 shares of the biotechnology company’s stock, valued at approximately $18,139,000.
Other hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Grifols by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 1,212 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 4,604 shares during the period. Allworth Financial LP lifted its stake in shares of Grifols by 15.7% in the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,096 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Grifols by 109.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 4,518 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Grifols in the 2nd quarter worth $95,000.
Grifols Stock Up 0.1%
Shares of NASDAQ GRFS opened at $7.34 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. Grifols, S.A. has a 52 week low of $7.32 and a 52 week high of $11.14. The firm has a 50-day moving average price of $8.04 and a 200 day moving average price of $8.58. The stock has a market capitalization of $5.00 billion, a price-to-earnings ratio of 38.63, a price-to-earnings-growth ratio of 0.28 and a beta of 0.65.
Analyst Ratings Changes
Several research firms have recently commented on GRFS. Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, Zacks Research cut shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $10.00.
Read Our Latest Research Report on GRFS
About Grifols
Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.
The company operates three main business units.
See Also
- Five stocks we like better than Grifols
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
